Endometrial Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Endometrial Cancer is a ~$89M Part D market in early consolidation, dominated by a single nuclear export inhibitor.
Key Trends
- Selinexor (XPOVIO) commands 96% of attributable spending, creating a highly concentrated market
- Dostarlimab (JEMPERLI) PD-1 checkpoint inhibitor gaining traction as primary indication expands in early-stage disease
- Older hormonal/cytotoxic agents (progesterone, anthracyclines, megestrol) declining as immuno-oncology reshapes standard of care
Career Verdict
Endometrial cancer offers emerging opportunity in immunotherapy and precision oncology, but current market size is modest; best suited for specialists willing to grow with the indication rather than high-volume revenue-chase roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | XPOVIO (selinexor) | Mthera Pharma | $86M | — | Peak | Stable | 9.3yr |
| 2 | JEMPERLI (dostarlimab) | GSK | $2M | — | Peak | Growing |
Drug Class Breakdown
Selinexor dominance, but myelosuppression limits broader adoption
Early growth in MSI-H/dMMR populations, expanding label potential
Declining use; approaching loss of exclusivity, legacy indications only
Career Outlook
StableEndometrial cancer remains a small but growing indication within oncology, driven by dosarlimab's label expansion in early-stage, MSI-H disease. Market consolidation around selinexor and dostarlimab creates clarity on competitive landscape, but modest revenue base limits traditional pharma job creation. Best suited for specialists seeking deep expertise in precision oncology and immunotherapy rather than high-volume commercial roles.
Breaking In
Start in broader oncology at a Tier 1 player (GSK, AbbVie, J&J), build checkpoint inhibitor or nuclear export expertise, then pivot to endometrial-focused team or biotech; avoid endometrial-only roles early in career due to niche size.
For Experienced Professionals
If you have 5+ years in gynecologic or immunotherapy oncology, GSK's dostarlimab franchise offers direct leadership opportunity; alternatively, lead biotech focusing on checkpoint/selinexor combinations can offer equity upside and strategic influence.
In-Demand Skills
Best For
Hiring Landscape
Endometrial cancer oncology hires are concentrated in commercial (1,118 roles, avg $255K) and clinical operations (259 roles, avg $307K), with disproportionate demand for Medical Affairs specialists ($302K). Top oncology employers (J&J, AbbVie, Takeda, AstraZeneca) are hiring broadly in oncology, but endometrial-specific teams remain small. GSK is the primary player in this indication, with 732 jobs in oncology broadly, but endometrial-focused hiring is minimal.
Top Hiring Companies
By Department
Endometrial cancer hires are niche within large oncology organizations; specialist roles (MSL, clinical ops) command premium pay, but volume is low; seek opportunities at GSK (dostarlimab expansion) or emerging biotech focusing on checkpoint or nuclear export inhibitor combinations.
On Market (1)
Approved therapies currently available
Competitive Landscape
49 companies ranked by most advanced pipeline stage
+19 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 9,827 patients across 50 trials
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
ALPINE: Maintenance Letrozole/Abemaciclib
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Abemaciclib and Letrozole to Treat Endometrial Cancer
ZW25 in Women With Endometrial Cancers
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Pembro/Carbo/Taxol in Endometrial Cancer
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
Exemestane in Advanced and Recurrent Endometrial Carcinoma
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
Aminopterin in Treating Patients With Refractory Leukemia
PRO1107 in Patients With Advanced Solid Tumors
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Related Jobs in Oncology
DMPK Scientist
Clinical Oncology Specialist
Director Group Patents
Territory Manager- Flanders
Security Governance Specialist
Document Controller
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.